Safety and stable survival of stem-cell-derived retinal organoid for 2 years in patients with retinitis pigmentosa
Yasuhiko Hirami,Michiko Mandai,Sunao Sugita,Akiko Maeda,Tadao Maeda,Midori Yamamoto,Hirofumi Uyama,Satoshi Yokota,Masashi Fujihara,Masataka Igeta,Takashi Daimon,Kanako Fujita,Tomoko Ito,Naoki Shibatani,Chikako Morinaga,Tetsuya Hayama,Aya Nakamura,Kazuki Ueyama,Keiichi Ono,Hidetaka Ohara,Masayo Fujiwara,Suguru Yamasaki,Kenji Watari,Kiyoko Bando,Keigo Kawabe,Atsushi Ikeda,Toru Kimura,Atsushi Kuwahara,Masayo Takahashi,Yasuo Kurimoto
DOI: https://doi.org/10.1016/j.stem.2023.11.004
IF: 23.9
2023-12-07
Cell Stem Cell
Abstract:Transplantation of induced pluripotent stem cell (iPSC)-derived retinal organoids into retinal disease animal models has yielded promising results, and several clinical trials on iPSC-derived retinal pigment epithelial cell transplantation have confirmed its safety. In this study, we performed allogeneic iPSC-derived retinal organoid sheet transplantation in two subjects with advanced retinitis pigmentosa (jRCTa050200027). The primary endpoint was the survival and safety of the transplanted retinal organoid sheets in the first year post-transplantation. The secondary endpoints were the safety of the transplantation procedure and visual function evaluation. The grafts survived in a stable condition for 2 years, and the retinal thickness increased at the transplant site without serious adverse events in both subjects. Changes in visual function were less progressive than those of the untreated eye during the follow-up. Allogeneic iPSC-derived retinal organoid sheet transplantation is a potential therapeutic approach, and the treatment's safety and efficacy for visual function should be investigated further.